Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects are eligible for enrolment in the study if they have previously participated in an eltrombopag study, either phase II or III, and meet all of the following criteria:
Subject has signed and dated a written informed consent for this study.
Subject has previously participated in a study evaluating eltrombopag, either phase II or III, and must have received at least one dose of study medication (either active drug or placebo). This excludes subjects from phase I studies (See Section 5.1).
The prescribed follow-up ophthalmic assessment at 6 months post end of treatment should be completed as specified in the protocol for the previous study.
Subject is able to understand and comply with protocol requirements and instructions.
You may not be if
Subjects meeting any of the following criteria must not be enrolled in the study:
Subject has received surgery for cataracts and is aphakic or bilaterally pseudophakic.
In some countries (i.e. France), a subject is neither affiliated with nor a beneficiary of a social security category.
Clareo Health | LENS - Long-term Eltrombopag Observational Study
